



## Grant of Stock Options and Exercise of Stock Options

**San Diego, California and Sydney, Australia (Friday, 10 November 2017 AEST)** – REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) announces that a total of 240,000 options to purchase common stock (equivalent to 2,400,000 CDIs) were granted to employees of the Company under the Company’s Amended and Restated 2010 Equity Incentive Plan. Additionally, the Company issued 13,803 shares of common stock (equivalent to 138,030 CDIs) upon the exercise of employee stock options. The options had been issued under the Company’s Amended and Restated 2010 Equity Incentive Plan. Details of the exercise are provided in the attached Appendix 3B.

Following the grants and the exercise, there are outstanding options to purchase a total of 6,567,148 shares of common stock (equivalent to 65,671,480 CDIs) and a total of 593,100 RSUs (equivalent to 5,931,000 CDIs) outstanding and subject to vesting under the Company’s equity incentive plans.

### About REVA

REVA is a medical device company located in San Diego, California, USA, that has developed and commercialized a proprietary bioresorbable scaffold, as an alternative to metal stents, to treat coronary artery disease. Scaffolds provide restoration of blood flow, support the artery through the healing process, then disappear (or “resorb”) from the body over a period of time. This resorption allows the return of natural movement and function of the artery, a result not attainable with permanent metal stents. The Company’s Fantom® scaffold, which received European CE Marking on April 3, 2017, is designed to offer an ideal balance of thinness and strength, with distinct ease-of-use features including complete scaffold visibility under x-ray, expansion with one continuous inflation, and no procedural time limitations.

### Forward-Looking Statements

*This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management. All statements that are not statements of historical fact, including statements that address future operating plans or performance and events or developments that may occur in the future, are forward-looking statements, such as those statements regarding the projections and timing surrounding commercial operations and sales, clinical trials, pipeline product development, and future financings. No undue reliance should be placed on forward-looking statements. Although management believes forward-looking statements are reasonable as and when made, forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to vary materially from those expressed in forward-looking statements, including the risks and uncertainties that are described in the "Risk Factors" section of REVA's Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on February 28, 2017 and as updated in periodic reports thereafter. Any forward-looking statements in this announcement speak only as of the date when made. REVA does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.*

**United States  
Investor & Media Enquiries:**  
REVA Medical, Inc.  
Cheryl Liberatore  
Director, Communications  
+1 858-966-3045

**Australia  
Investor Enquiries:**  
Inteq Limited  
Kim Jacobs  
+61 438 217 279  
Andrew Cohen  
+61 408 333 452

**Australia  
Media Enquiries:**  
Buchan Consulting  
Rebecca Wilson  
+61 3 9866 4722

# Appendix 3B

## New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

REVA Medical, Inc.

ARBN

146 505 777

We (the entity) give ASX the following information.

### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1	+Class of +securities issued or to be issued	1) Options to purchase shares of common stock ("Options") (unquoted). 2) Common stock ("Stock")(quoted).
2	Number of +securities issued or to be issued (if known) or maximum number which may be issued	1) 240,000 Options (equivalent to 2,400,000 CDIs). 2) 13,803 shares of Stock (equivalent to 138,030 CDIs).
3	Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)	1) 205,988 non-statutory ("NSO") and 34,012 incentive ("ISO") Options. Each Option is issued for no monetary consideration and, upon vesting, entitles the holder to purchase one share of common stock for a price of US\$5.88. Each Option has a 10-year term, is immediately exercisable, and is issued in accordance with the Company's Amended and Restated 2010 Equity Incentive Plan. Options vest over four years with 25% of each Option vesting on the first annual anniversary of grant date and 2.0833% vesting on each monthly anniversary thereafter. Vesting is conditioned upon the holder's remaining in service to the Company at the vesting date. 2) Shares of fully paid Stock in REVA Medical, Inc.
4	Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities? If the additional +securities do not rank equally, please state: <ul style="list-style-type: none"> <li>• the date from which they do</li> </ul>	1) The holders of Options are not entitled to any rights of stockholders. Upon the exercise of the Options for shares of common stock, the shares of common stock (which can be converted to CDIs) will rank equally in all respects with the existing class of quoted securities. 2) Yes.

+ See chapter 19 for defined terms.

	<ul style="list-style-type: none"> <li>the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul>	
5	Issue price or consideration	<ol style="list-style-type: none"> <li>No monetary consideration is payable for the issuance of the Options.</li> <li>9,622 at US\$3.80 per share net exercise of 27,762 shares; 939 at US\$4.00 per share net exercise of 2,916 shares; 3,242 at US\$5.10 per share net exercise of 26,000 shares</li> </ol>
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	<ol style="list-style-type: none"> <li>Options were granted as incentive and inducement for new employees.</li> <li>Issuance of 13,803 shares of Stock upon the exercise of 56,678 stock options.</li> </ol>
6a	Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h for securities the subject of this Appendix 3B, and comply with section 6i	No.
6b	The date the security holder resolution under rule 7.1A was passed	Not applicable.
6c	Number of +securities issued without security holder approval under rule 7.1	Not applicable.
6d	Number of +securities issued with security holder approval under rule 7.1A	Not applicable.
6e	Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Not applicable.
6f	Number of +securities issued under an exception in rule 7.2	<ol style="list-style-type: none"> <li>240,000 Options (Listing Rule 7.2, exception 9).</li> <li>13,803 shares of Stock (Listing Rule 7.2, exception 4).</li> </ol>
6g	If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.	Not applicable.

+ See chapter 19 for defined terms.

6h If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements

Not applicable.

6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements

Not applicable.

7 +Issue dates  
 Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B.

1) Options were granted 18 September 2017.  
 2) Stock was issued on 22 September 2017 and 26 September 2017.

	Number	+Class
8 Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable)	412,458,200 CDIs are quoted, assuming all shares of common stock are held as CDIs (a total of 41,245,820 common shares are issued and outstanding).	CDIs

	Number	+Class
9 Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)	372,925 options (over 372,925 shares of common stock or 3,729,250 CDIs).  6,194,223 options (over 6,194,223 shares of common stock or 61,942,230 CDIs).  593,100 RSUs (over 593,100 shares of common stock or 5,931,000 CDIs).  250 convertible notes.  471 convertible notes.  2,119,500 options (over 2,119,500 shares of common stock or 21,195,000 CDIs).	Options issued under the 2001 Stock Option/Stock Issuance Plan.  Options issued under the Amended and Restated 2010 Equity Incentive Plan.  RSUs issued under the Amended and Restated 2010 Equity Incentive Plan.  Convertible notes issued under Convertible Note Deed dated 25 September 2014.  Convertible notes issued under Convertible Note Deed dated 22 April 2017.  Options issued under Convertible Note Deed dated 22 April 2017.

10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

Not applicable.

## Part 2 - Pro rata issue

11 Is security holder approval required?

Not applicable.

+ See chapter 19 for defined terms.

12	Is the issue renounceable or non-renounceable?	Not applicable.
13	Ratio in which the +securities will be offered	Not applicable.
14	+Class of +securities to which the offer relates	Not applicable.
15	+Record date to determine entitlements	Not applicable.
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	Not applicable.
17	Policy for deciding entitlements in relation to fractions	Not applicable.
18	Names of countries in which the entity has security holders who will not be sent new offer documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	Not applicable.
19	Closing date for receipt of acceptances or renunciations	Not applicable.
20	Names of any underwriters	Not applicable.
21	Amount of any underwriting fee or commission	Not applicable.
22	Names of any brokers to the issue	Not applicable.
23	Fee or commission payable to the broker to the issue	Not applicable.
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	Not applicable.
25	If the issue is contingent on security holders' approval, the date of the meeting	Not applicable.
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	Not applicable.
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	Not applicable.
28	Date rights trading will begin (if applicable)	Not applicable.
29	Date rights trading will end (if applicable)	Not applicable.

---

+ See chapter 19 for defined terms.

- 30 How do security holders sell their entitlements *in full* through a broker?
- 31 How do security holders sell *part* of their entitlements through a broker and accept for the balance?
- 32 How do security holders dispose of their entitlements (except by sale through a broker)?
- 33 <sup>+</sup>Issue date

### Part 3 - Quotation of securities

*You need only complete this section if you are applying for quotation of securities*

- 34 Type of <sup>+</sup>securities  
(*tick one*)
- (a)  <sup>+</sup>Securities described in Part 1
- (b)  All other <sup>+</sup>securities  
Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

#### Entities that have ticked box 34(a)

##### Additional securities forming a new class of securities

*Tick to indicate you are providing the information or documents*

- 35  If the <sup>+</sup>securities are <sup>+</sup>equity securities, the names of the 20 largest holders of the additional <sup>+</sup>securities, and the number and percentage of additional <sup>+</sup>securities held by those holders
- 36  If the <sup>+</sup>securities are <sup>+</sup>equity securities, a distribution schedule of the additional <sup>+</sup>securities setting out the number of holders in the categories  
1 - 1,000  
1,001 - 5,000  
5,001 - 10,000  
10,001 - 100,000  
100,001 and over
- 37  A copy of any trust deed for the additional <sup>+</sup>securities

#### Entities that have ticked box 34(b)

- 38 Number of <sup>+</sup>securities for which <sup>+</sup>quotation is sought
- 39 <sup>+</sup>Class of <sup>+</sup>securities for which quotation is sought

---

<sup>+</sup> See chapter 19 for defined terms.

40 Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?  
 If the additional +securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

Not applicable.

41 Reason for request for quotation now  
 Example: In the case of restricted securities, end of restriction period  
 (if issued upon conversion of another +security, clearly identify that other +security)

Not applicable.

42 Number and +class of all +securities quoted on ASX  
 (including the +securities in clause 38)

Number	+Class
Not applicable.	Not applicable.

**Quotation agreement**

1 +Quotation of our additional +securities is in ASX’s absolute discretion. ASX may quote the +securities on any conditions it decides.

2 We warrant the following to ASX.

- The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
- There is no reason why those +securities should not be granted +quotation.
- An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

4 We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:           /s/ Brandi L. Roberts            
 (Company Secretary)

Date: 10 November 2017

Print name: Brandi L. Roberts

== == == == ==

---

+ See chapter 19 for defined terms.